ArticleJournal of the American Heart Association2026
Prognostic Value of Right Atrial Strain in Patients With Moderate-to-Severe Tricuspid Regurgitation.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSignificant tricuspid regurgitation (TR) leads to right ventricular dysfunction and associated comorbidities. As the receiving chamber for regurgitant volume, the right atrium undergoes significant mechanical remodeling. This study investigated whether right atrial reservoir strain (RArS), a key marker of atrial mechanics, serves as a prognostic indicator for mortality in patients with moderate-to-severe TR.
methodsClinical, laboratory, and echocardiographic data from 289 consecutive patients with TR (grade ≥+3) were analyzed. RArS was evaluated by 2-dimensional speckle-tracking echocardiography using semiautomated software (TOMTEC; Philips). The cohort was divided into 2 groups by RArS above or below the median value.
resultsA total of 239 patients (mean age 82 years, 55% women) were included in the final study. Median RArS was 11.7%. Compared with patients with higher RArS, patients with RArS below median had a higher rate of atrial fibrillation and worse right ventricular function. Lower RArS was also associated with wider inferior vena cava diameter, abnormal cholestatic liver enzymes, and a higher rate of diuretic use. During a median follow-up period of 26 months (interquartile range, 8-31), 99 (41%) patients died. Patients with RArS <11.7% had significantly lower survival rates (52% versus 30%;
conclusionsImpaired RArS assessed by echocardiography is independently associated with all-cause mortality in patients with moderate-severe TR. Serial measurement of RArS can potentially aid in optimizing timing for intervention in patients with TR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.